Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON-SWITCH-SZ: switch from semaglutide 2.4 mg to zovaglutide in adults with obesity
CTR20263328Phase 2Active
- Sponsor
- Quality Peptide
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zovaglutide in obesity (3 arms), sponsored by Quality Peptide. Primary endpoint: Proportion of participants successfully switched to zovaglutide injection. Started Sep 2026; status: active.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20263328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263328.